DALLAS & SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone. This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs..

达拉斯和旧金山--（商业新闻短讯）--透明且100%通过PBM的SmithRx和Mark Cuban Cost Plus Drug Company PBC（Cost Plus Drugs）今天宣布，仅在6个月内，他们就为SmithRx的客户节省了950多万美元的自身免疫类别。这一里程碑是通过战略性地采购净成本最低的自身免疫药物实现的，包括通过成本加成药物向成本效益高的替代品的有效转变。。

This successful alliance combines SmithRx's patient-first approach with Cost Plus Drugs’ revolutionary drug pricing strategy to tackle the highest cost drug category for many employers. Driven by overwhelming demand by employers, SmithRx and Cost Plus Drugs have set a new benchmark for value and affordability in healthcare.

这一成功的联盟将SmithRx的患者至上方法与Cost Plus Drugs的革命性药物定价策略相结合，以应对许多雇主的最高成本药物类别。在雇主压倒性需求的驱动下，SmithRx和成本加成药物为医疗保健的价值和负担能力树立了新的基准。

This, in turn, has made a significant impact on the lives of patients needing these critical medications..

反过来，这对需要这些关键药物的患者的生活产生了重大影响。。

Key highlights of the successful implementation include:

成功实施的关键要点包括：

Strategic Drug Sourcing: By leveraging Cost Plus Drugs’ transparent pricing model, SmithRx employer clients elect to source select autoimmune medications at the lowest possible net cost, sharing these savings with their members.

战略性药物采购：通过利用成本加成药物的透明定价模式，SmithRx雇主客户选择以尽可能低的净成本采购选择的自身免疫药物，并与成员分享这些节省的费用。

Seamless Patient Transition: The collaboration ensures that patients are transitioned smoothly to more affordable medications without disrupting their treatment. Educational resources and support are provided to both patients and healthcare providers to facilitate informed decision-making.

无缝的患者过渡：这种合作确保患者在不中断治疗的情况下顺利过渡到更实惠的药物。向患者和医疗保健提供者提供教育资源和支持，以促进知情决策。

Unprecedented Savings: The initiative has realized $9.5 million in savings within the autoimmune drug category, demonstrating the potential for significant healthcare cost reductions without compromising on quality or efficacy.

前所未有的节约：该计划在自身免疫药物类别中实现了950万美元的节约，证明了在不影响质量或疗效的情况下大幅降低医疗保健成本的潜力。

Innovative Approach to Pharmacy Benefits: This work exemplifies how innovative approaches to drug sourcing and pharmacy benefits management can result in substantial cost savings and better access to necessary treatments.

创新的药房收益方法：这项工作举例说明了创新的药物采购和药房收益管理方法如何能够节省大量成本并更好地获得必要的治疗。

Dr. Alex Oshmyansky, founder of Cost Plus Drugs, stated, 'Working with SmithRx has allowed us to extend the reach of our cost-plus model, bringing essential autoimmune medications to more patients at significantly lower prices. This is a prime example of how transparency and innovation in drug pricing can directly benefit consumers.'.

Cost Plus Drugs创始人亚历克斯·奥什米扬斯基（AlexOshmyansky）博士表示，“与SmithRx合作，使我们能够扩大Cost Plus模型的范围，以更低的价格为更多患者提供必要的自身免疫药物。这是药品定价的透明度和创新如何直接惠及消费者的一个典型例子。”。

Jake Frenz, CEO of SmithRx, added, 'Our collaboration with Mark Cuban Cost Plus Drug Company is a cornerstone of our strategy to manage healthcare costs effectively while ensuring patients receive the best possible care. The $9.5 million in savings is just the beginning, and we are excited about the future of this relationship.'.

SmithRx首席执行官杰克·弗伦茨（JakeFrenz）补充道，“我们与马克·库班成本加成制药公司（Mark Cuban Cost Plus Drug Company）的合作是我们有效管理医疗保健成本，同时确保患者获得尽可能最佳护理的战略基石。950万美元的节省只是个开始，我们对这种关系的未来感到兴奋。”。

This milestone announcement comes on the heels of SmithRx's recent Series C financing round, which saw the company secure $60 million in funding led by top Silicon Valley healthcare venture capital firm Venrock.

这一里程碑式的宣布紧随SmithRx最近的C轮融资之后，该公司获得了由硅谷顶级医疗保健风险投资公司Venrock牵头的6000万美元资金。

About Mark Cuban Cost Plus Drug Company

关于Mark Cuban Cost Plus制药公司

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells.

Mark Cuban Cost Plus制药公司PBC（Cost Plus Drugs）旨在从根本上改变制药行业的运营方式。作为一家公益性公司，其改善公众健康的社会使命与底线同样重要。成本加成药物透明地对其销售的每种药物收取标准加价。

The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide..

costplusdrugs.com在线药房于2022年1月推出，目前拥有2300多种处方药，每天通过邮件发送给数千名快乐的顾客。客户还可以通过团队古巴卡前往参与的零售药店接受成本加成药物定价。成本加成药物正在与健康计划、管理式护理组织、药房福利管理人（PBM）和自保雇主合作，为全国雇主赞助的福利计划带来同样的节省。。

About SmithRx:

关于SmithRx：

SmithRx is working to reduce the complexity and cost of pharmacy benefits by building a new type of pharmacy benefits manager (PBM) committed to transparency and aligned with employers and patients. By combining advanced technology, a member-centric approach, and innovative cost savings programs, we're making prescriptions more affordable and delivering valuable transparency and savings to main street businesses..

SmithRx正在通过建立一种新型的药房福利管理器（PBM）来降低药房福利的复杂性和成本，该管理器致力于透明度，并与雇主和患者保持一致。通过结合先进技术、以会员为中心的方法和创新的成本节约计划，我们正在使处方更实惠，并为主要街道企业提供有价值的透明度和节约。。